Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

Ozempic and Wegovy have become popular options for people looking to lose weight, but there are some risks and side effects ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...